219 related articles for article (PubMed ID: 28064543)
1. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
Dogra S; Uprety S; Suresh SH
Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD6 mAbs for the treatment of psoriasis.
Dogra S; D S; Rajagopalan M
Expert Opin Biol Ther; 2020 Oct; 20(10):1215-1222. PubMed ID: 32466689
[TBL] [Abstract][Full Text] [Related]
3. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
Loganathan S; Athalye SN; Joshi SR
Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
[TBL] [Abstract][Full Text] [Related]
4. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z
MAbs; 2014; 6(3):783-93. PubMed ID: 24594862
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
[TBL] [Abstract][Full Text] [Related]
7. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
[TBL] [Abstract][Full Text] [Related]
8. Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody.
Gupta A; Sharma YK; Deo K; Kothari P
Indian J Dermatol Venereol Leprol; 2016; 82(4):459-61. PubMed ID: 27279321
[No Abstract] [Full Text] [Related]
9. Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.
Menon R; David BG
Clin Cosmet Investig Dermatol; 2015; 8():215-22. PubMed ID: 25945063
[TBL] [Abstract][Full Text] [Related]
10. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
[TBL] [Abstract][Full Text] [Related]
11. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
Rodríguez PC; Prada DM; Moreno E; Aira LE; Molinero C; López AM; Gómez JA; Hernández IM; Martínez JP; Reyes Y; Milera JM; Hernández MV; Torres R; Avila Y; Barrese Y; Viada C; Montero E; Hernández P
Clin Exp Immunol; 2018 Feb; 191(2):229-239. PubMed ID: 28963724
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India.
Budamakuntla L; Shree-Lakshmi HV; Bansal A; Venkatarayaraju SK
Psoriasis (Auckl); 2019; 9():19-27. PubMed ID: 31119094
[TBL] [Abstract][Full Text] [Related]
13. Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis.
Pai G; Pai AH
Case Rep Dermatol; 2017; 9(2):141-145. PubMed ID: 29033818
[TBL] [Abstract][Full Text] [Related]
14. Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience.
Budamakuntla L; Madaiah M; Sarvajnamurthy S; Kapanigowda S
Clin Exp Dermatol; 2015 Mar; 40(2):152-5. PubMed ID: 25495868
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program.
Falcón Lincheta L; Saumell Nápoles Y; Gray Lovio OR; Viqueira Fuentesfría AM; Pérez Alonso T; Batista Romagoza M; Urquiza Rodríguez A; Mantecón Fernández B; Bautista Jerez HA; Fernández de Armas D; Martínez Matute ES; León García Y; Oramas Fernández DK; Marrero Chavez Y; Fernandez Lorente A; Valls Hung AR; Lorenzo-Luaces P; Valenzuela Silva C; Moreno E; Hernández-Casaña P
Int Immunopharmacol; 2024 Jun; 134():112225. PubMed ID: 38759368
[TBL] [Abstract][Full Text] [Related]
16. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A
Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150
[TBL] [Abstract][Full Text] [Related]
17. CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action.
Garner LI; Hartland A; Breuning J; Brown MH
Immunology; 2018 Oct; 155(2):273-282. PubMed ID: 29772075
[TBL] [Abstract][Full Text] [Related]
18. Clinical and experimental evidence for targeting CD6 in immune-based disorders.
Consuegra-Fernández M; Lin F; Fox DA; Lozano F
Autoimmun Rev; 2018 May; 17(5):493-503. PubMed ID: 29526637
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions.
Singh V
Dermatol Res Pract; 2016; 2016():1316326. PubMed ID: 27885324
[TBL] [Abstract][Full Text] [Related]
20. CD6 as a potential target for treating multiple sclerosis.
Li Y; Singer NG; Whitbred J; Bowen MA; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2687-2692. PubMed ID: 28209777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]